Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million all-stock deal, according to reports from TechCrunch in early April 2026. The acquisition, which closed in early April, brings a small team of fewer than 10 employees focused on AI-powered drug discovery into Anthropic's healthcare life sciences division.
Coefficient Bio Brings Drug Discovery Expertise to Anthropic
Coefficient Bio was founded eight months ago by Samuel Stanton and Nathan C. Frey, both former computational drug discovery researchers at Genentech's Prescient Design group. The startup developed a platform using AI for planning drug research and development, managing clinical regulatory strategy, and identifying new drug opportunities. Despite operating in stealth mode since its August 2025 launch, the company attracted Anthropic's attention for its specialized approach to pharmaceutical AI applications.
The Deal Represents Minimal Dilution for Anthropic Shareholders
The $400 million acquisition price represents approximately 0.1% dilution for Anthropic's existing shareholders, measured against the company's $380 billion post-money valuation from its $30 billion Series G funding round completed in February 2026. The all-stock structure allows Anthropic to preserve cash while integrating specialized biotech talent and technology into its expanding healthcare initiatives.
Acquisition Follows Anthropic's October 2025 Healthcare Push
The Coefficient Bio deal extends Anthropic's healthcare strategy, which gained momentum with the October 2025 launch of Claude for Life Sciences. That tool aims to help scientific researchers accelerate discovery workflows. The Coefficient Bio team will join Anthropic's healthcare life sciences group, bringing wet-lab expertise and regulatory knowledge to complement Claude's computational capabilities.
AI Labs Race Into Drug Discovery and Biological Research
The acquisition reflects a broader industry pattern of major AI labs building in-house biological research capabilities. Google DeepMind operates Isomorphic Labs and licenses AlphaFold for drug discovery applications. OpenAI has established pharmaceutical partnerships with companies like Moderna. NVIDIA recently committed $1 billion to collaborate with Eli Lilly on AI-driven drug development, while Eli Lilly separately invested $2.75 billion in Insilico Medicine. Anthropic's acquisition of Coefficient Bio positions the company to compete directly in wet-lab validation and biological data generation, rather than relying solely on computational tools or external partnerships.
Key Takeaways
- Anthropic acquired Coefficient Bio for $400 million in all-stock, representing 0.1% dilution against its $380 billion valuation
- Coefficient Bio's founders previously worked in computational drug discovery at Genentech's Prescient Design group
- The acquisition extends Anthropic's healthcare strategy following its October 2025 Claude for Life Sciences launch
- Major AI labs including Google DeepMind, OpenAI, and NVIDIA have all established drug discovery initiatives
- The Coefficient Bio team of fewer than 10 employees brings wet-lab validation capabilities to Anthropic's life sciences division